Experimental Lung Cancer Drug Shows 34% Reduction in Risk of Death in Late-Stage Trial
An experimental lung cancer drug developed by Akeso and Summit Therapeutics showed a statistically significant improvement in survival rates, reducing the risk of death by 34% when combined with chemotherapy. The Phase 3 trial was conducted exclusively in China.
Topics: bispecific antibodies Harmoni-6 trial lung cancer PD-1/VEGF drugs